1 Memorial Sloan-Kettering Cancer Center and Weill Cornell ...

Experimental Therapeutics Center Program Project Grant(Project 4) (Project 4 PI:Brentjens)MSKCCMultimodal Cure of ALLCOMPLETED (within past three years)04/01/09-03/31/14$180,000(Annually)10%Geoffrey Beene Cancer Research Fund Award (PI: 12/1/2007 - 11/30/2009Brentjens)$130,000 (Annually)Genetic Modifications to enhance the in vivo survival and Anti-Tumor Activity of GeneModified CD19-Targeted T cellsExperimental Therapeutics Center Grant (Project 1 PI:Brentjens)MSKCC6/1/2005 - 5/31/2010$95,000 (Annually)In vitro and In vivo Pre-Clincal Analysis of ALL and MCL patient -derived tumor targeted TcellsTranslational and Integrative Medicine Fund Research 1/1/08 - 12/31/2010Grant (PI: Brentjens)$150,000 (Annually)Development of a novel approach to the treatment of Advanced Ovarian Cancer UtilizingAutologous T Cells Targeted to the MUC-16 AntigenDamon Runyon Clinical Investigator Award (PI: Brentjens) 7/1/2006 - 6/30/2011Damon Runyon Foundation$150,000 (Annually)Adoptive Therapy of B cell Leukemias with Genetically Modified Autologous T Cells15%10%20%MENTEE AWARDSGC219368 (PI: Schultz)(Mentor: Brentjens)7/1/2012 - 6/30/2014St. Baldrick's Foundation$92,391Improving Outcomes in Pediatric Leukemia using Adoptive ImmunotherapyK. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES(e.g., Invited lectures, Journal reviewer, NIH study section, etc)Invited lecturesDateLecture and venue11/1/03-11/06/03 Salzburg Medical Seminars Oncology 2003. Faculty Member, Salzburg, Austria6/10/2004 “Targeting Leukemia with Genetically Enhanced T Lymphocytes”, TranslationalResearch Seminar Series, Memorial Sloan-Kettering Cancer Center, New York,NY2/15/2006 Hematology/Oncology Grand Rounds New York Presbyterian Hospital, WeillMedical College, New York, NY9